Intrinsiqq
Dermata Therapeutics Inc. logo

Dermata Therapeutics Inc. Financials

DRMA

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 6 available years
Income Statement
DEC 2025
6:1 split
DEC 2024
~7.8:1 split
DEC 2023
~3.8:1 split
DEC 2022
~1.5:1 split
DEC 2021
Operating Expenses
Selling & Marketing$1––––
General & Administrative$5$4$4$4$4
Research & Development$3$8$4$6$3
Total Operating Expenses$8$13$8$10–
Operating Income-$8-$13-$8-$10-$8
Non-Operating
Net Interest Expense$0$0––-$0
Income Tax Expense–$0$0$0$0
Net Income
Net Income-$8-$12-$8-$10-$8
EPS (Basic)-$8.16-$80.32-$399.90-$2,088.00-$5,832.00
EPS (Diluted)-$8.16-$80.32-$399.90-$1,871.97-$2,277.20
Weighted Avg Shares (Basic)926,192152,974––4.3M
Weighted Avg Shares (Diluted)926,1921.5M194,928––
Shares Outstanding926,192152,977.219,492.85,134.1033,470.262

Dermata Therapeutics (DRMA) financials: revenue, profit and margins

Dermata Therapeutics (DRMA) generated about n/a in revenue and -$9 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Dermata Therapeutics profitable?+

Dermata Therapeutics reported about -$9 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 9 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 10 Nov 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with DRMA

CompareIntrinsic value
NXTCNextCure, Inc.
$6.45-4.87%40
GANXGain Therapeutics Inc.
$1.00-4.86%25
KURAKura Oncology Inc.
$6.91-5.99%10
IRDOpus Genetics Inc.
$3.99-2.21%10
PVCTProvectus Biopharmaceuticals, Inc.
$0.05+1.11%6
VSTMVerastem Inc.
$6.33-7.73%40
LXRXLexicon Pharmaceuticals, Inc.
$1.53-8.38%40
COLLCollegium Pharmaceutical Inc.
$24.72-1.94%85

Spot a number that looks wrong? Check it in DRMA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing DRMA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.